Thoracic Aortic Aneurysm Market By Treatment Approach (Thoracic Endovascular Aortic Repair [TEVAR][Branched Endovascular Repair], Hybrid/Open-Stent Repair [Frozen Elephant Trunk Procedures], Conventional Open Surgical Repair); By Product Type (Thoracic Endovascular Stent Grafts [Standard and Branched], Hybrid/Open-Stent Graft Systems, Conventional Surgical Aortic Grafts, Procedure-Specific Accessories); By Aneurysm Location (Aortic Root & Ascending Aortic Aneurysms, Aortic Arch Aneurysms, Descending Thoracic Aortic Aneurysms); By Procedure Urgency (Elective Repair, Urgent/Emergency Repair); By End User (Multispecialty Hospitals, Specialized Cardiac & Vascular Hospitals); By Geography (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa), Segment Revenue Estimation, Forecast, 2026–2032

How Are Branched Stent Grafts and Complex Aortic Repair Expanding the Thoracic Aortic Aneurysm Market? – (Updated On: 11th-Oct-2026)

The Global Thoracic Aortic Aneurysm Market was valued at USD 770 million in 2025 and is projected to reach USD 1.33 billion by 2032, expanding at a CAGR of 8.1% during 2026–2032, according to Strategic Market Research.

 

Thoracic aortic aneurysm (TAA) refers to an abnormal enlargement or bulging of a weakened section of the aorta, the body's main blood vessel that carries oxygen-rich blood from the heart to the rest of the body.

 

Thoracic aortic aneurysm (TAA) affects an estimated 545,000 people in the United States and approximately 13.1 million people globally, based on population-level prevalence estimates. Approximately 18,000 new cases occur annually in the United States and 435,000 worldwide, reflecting the substantial patient population requiring cardiovascular monitoring and specialized aortic care. Population-based estimates also suggest approximately 5,400 TAA ruptures annually in the United States.

 

The Market is increasingly influenced by minimally invasive repair technologies, advanced cardiovascular imaging, and innovation in complex aortic reconstruction. W. L. Gore & Associates' FDA-approved GORE TAG Thoracic Branch Endoprosthesis, approved in 2022, uses branched stent-graft technology to treat selected thoracic aortic lesions while preserving blood flow to major branch vessels. Emerging endovascular technologies are expanding treatment options for patients with complex aortic anatomy, while CT angiography and three-dimensional procedural planning support treatment precision

 

Overall, the Thoracic Aortic Aneurysm Market is transitioning toward more specialized and minimally invasive treatment, supported by improvements in diagnostic imaging, branched stent-graft technologies, and complex aortic repair capabilities.

 

Which Thoracic Aortic Aneurysm Market Segments Are Leading Revenue and Recording the Fastest Growth?

By Treatment Approach: TEVAR Leads as Hybrid Repair Opens New Revenue Opportunities

Largest Subsegment — Thoracic Endovascular Aortic Repair (TEVAR)

Thoracic Endovascular Aortic Repair (TEVAR), including branched endovascular repair, accounted for an estimated 48% of the global Thoracic Aortic Aneurysm Market, valued at USD 369.6 million in 2025, and is projected to grow at a CAGR of 9.8% during 2026–2032. TEVAR has largely replaced open surgery as the preferred treatment for suitable descending thoracic aortic aneurysms, supported by its minimally invasive approach, lower perioperative complications, shorter hospital stays, and expanding use of branched stent-graft technologies for complex aortic anatomy.

Fastest-Growing Subsegment — Hybrid/Open-Stent Repair

Hybrid and open-stent repair approaches, including Frozen Elephant Trunk (FET) procedures and surgical debranching combined with Thoracic Endovascular Aortic Repair (TEVAR), are increasingly used to treat complex thoracic and thoracoabdominal aortic aneurysms involving the aortic arch and descending aorta. Within the global Thoracic Aortic Aneurysm Market, hybrid/open-stent repair accounted for an estimated 22% market share, valued at USD 169.4 million in 2025, and is projected to register the fastest CAGR of 10.5% during 2026–2032, supported by expanding treatment options for complex aortic disease.

 

By Product Type: Thoracic Stent Grafts Lead as Hybrid Systems Accelerate Growth

Largest Subsegment — Thoracic Endovascular Stent Grafts

Standard and branched thoracic endovascular stent grafts accounted for an estimated 51% of the Thoracic Aortic Aneurysm Market, representing USD 392.7 million in 2025, with a projected CAGR of 9.5% during 2026–2032. Used in thoracic endovascular aortic repair (TEVAR), stent grafts create an internal lining that isolates weakened or bulging sections of the thoracic aorta from blood flow. Increasing adoption of minimally invasive aneurysm repair, expanding treatment eligibility for complex aortic anatomies, and advancements in branched graft designs support market growth.

Fastest-Growing Subsegment — Hybrid/Open-Stent Graft Systems

Hybrid and open-stent graft systems accounted for approximately 21% of the global Thoracic Aortic Aneurysm Market, valued at USD 161.7 million in 2025, and are projected to register the fastest CAGR of 10.7% during 2026–2032. Their growing clinical adoption is associated with the Frozen Elephant Trunk (FET) technique, which enables surgeons to treat complex thoracic aortic aneurysms involving the aortic arch and proximal descending aorta. Increasing use of hybrid surgical approaches for extensive aortic disease supports continued market expansion.

 

By Aneurysm Location: Ascending Aortic Disease Anchors Revenue as Arch Repair Advances

Largest Subsegment — Aortic Root and Ascending Aortic Aneurysms

Aortic root and ascending aortic aneurysms accounted for an estimated 39% of the global Thoracic Aortic Aneurysm Market, valued at USD 300.3 million in 2025, with a projected CAGR of 5.7% during 2026–2032. Approximately 60% of all thoracic aortic aneurysms involve the aortic root or ascending aorta, making the proximal aorta the most commonly affected anatomical location. The high prevalence of proximal aortic disease contributes to surgical repair procedures, vascular graft utilization, and specialized cardiovascular treatment across major cardiac surgery centers worldwide.

Fastest-Growing Subsegment — Aortic Arch Aneurysms

Aortic arch aneurysms involve localized weakening and bulging of the curved portion of the thoracic aorta connecting the ascending and descending aorta. Within the global Thoracic Aortic Aneurysm Market, aortic arch aneurysms accounted for an estimated 25% market share, valued at USD 192.5 million in 2025. The category is projected to register the fastest CAGR of 11.3% during 2026–2032, supported by increasing adoption of complex endovascular arch repair procedures, hybrid surgical techniques, and specialized branched and fenestrated stent-graft technologies.

 

By Procedure Urgency: Elective Repair Leads Revenue and Growth Through Earlier Intervention

Largest and Fastest-Growing Subsegment — Elective Repair

Elective repair accounted for an estimated 76% of the Thoracic Aortic Aneurysm Market in 2025, with a market value of USD 585.2 million, and is projected to register the fastest CAGR of 8.5% during 2026–2032. Elective repair plays a critical role in preventing life-threatening aortic rupture and associated mortality through planned surgical or endovascular intervention before the weakened aortic wall fails. Increasing early diagnosis, routine aneurysm surveillance, and timely intervention among high-risk patients are supporting the growing adoption of elective procedures worldwide.

 

By End User: Multispecialty Hospitals Lead as Specialized Aortic Centers Gain Momentum

Largest Subsegment — Multispecialty Hospitals

Multispecialty hospitals accounted for an estimated 63% of the global Thoracic Aortic Aneurysm Market, valued at USD 485.1 million in 2025, and are projected to grow at a CAGR of 7.2% during 2026–2032. Their leading position reflects their critical, life-saving role in diagnosing and managing thoracic aortic aneurysms, which often progress without noticeable symptoms. Access to cardiovascular surgeons, advanced imaging, emergency surgical intervention, and specialized intensive care enables comprehensive treatment, particularly for patients requiring complex aortic repair, endovascular procedures, and long-term cardiovascular monitoring.

Fastest-Growing Subsegment — Specialized Cardiac and Vascular Hospitals

Specialized cardiac and vascular hospitals accounted for an estimated 37% of the global Thoracic Aortic Aneurysm Market, valued at USD 284.9 million in 2025, and are projected to register the fastest CAGR of 9.5% during 2026–2032. Their leading position reflects the concentration of multidisciplinary expertise in diagnosing, monitoring, and treating thoracic aortic aneurysms through open surgical and endovascular procedures. High patient volumes, advanced aortic imaging capabilities, and growing adoption of thoracic endovascular aortic repair (TEVAR) contribute to continued market expansion.

 

By Geography: North America Leads as Asia-Pacific Expands Advanced Aortic Care

Largest Regional Subsegment — North America

North America held an estimated 38% share of the global Thoracic Aortic Aneurysm Market, valued at USD 292.6 million in 2025, and is projected to grow at a CAGR of 7.2% during 2026–2032. An aging population, increasing prevalence of hypertension and cardiovascular diseases, and well-established healthcare infrastructure contribute to regional market expansion. The United States leads in thoracic aortic aneurysm diagnosis and treatment, supported by widespread access to advanced CT imaging, specialized cardiovascular centers, and growing adoption of thoracic endovascular aortic repair (TEVAR) procedures.

Fastest-Growing Regional Subsegment — Asia-Pacific

Asia-Pacific Thoracic Aortic Aneurysm Market accounted for an estimated 25% of the global market, valued at USD 192.5 million in 2025, and is projected to register the fastest regional CAGR of 10.5% during 2026–2032. Rising elderly populations, increasing diagnosis of aortic disorders, and greater access to cardiovascular imaging are contributing to earlier aneurysm detection. Expanding specialized cardiac care facilities in China, Japan, and India, alongside growing adoption of thoracic endovascular aortic repair (TEVAR), are accelerating treatment procedures and strengthening regional market growth.

 

Which Manufacturers Are Leading the Thoracic Aortic Aneurysm Market Through Advanced Aortic Repair Technologies?

Medtronic: Established Thoracic Stent-Graft Adoption and Long-Term Clinical Evidence

Medtronic is a prominent manufacturer of thoracic endovascular repair technologies, particularly its Valiant Captivia Thoracic Stent Graft System, designed for treating suitable descending thoracic aortic lesions, including aneurysms. According to Medtronic, the Valiant Captivia system has been selected for more than 200,000 patients worldwide across its indicated thoracic aortic applications. This reflects substantial clinical experience, although the figure includes conditions beyond thoracic aortic aneurysms.

In the company's VALOR II pivotal study, five-year follow-up demonstrated 89.3% of evaluated patients (50 of 56) had stable or decreasing aneurysm sac diameter, while no Type I or III endoleaks were reported among 60 evaluated patients. These results provide clinical evidence supporting the system's role in thoracic aortic intervention. Medtronic's competitive strength lies in its established device portfolio, delivery technology, and long-term clinical follow-up data.

W. L. Gore & Associates: Branched Endovascular Technology Expands Aortic Arch Treatment

W. L. Gore & Associates is another prominent manufacturer in the thoracic aortic repair market, with its GORE TAG Thoracic Branch Endoprosthesis (TBE) designed to treat suitable aortic arch and descending thoracic aortic lesions while preserving blood flow to a branch vessel.

In April 2025, the FDA approved expanded indications for the TAG TBE to include additional aortic arch lesions. In September 2025, Gore announced approval and licensing for use across Zones 0, 1, and 2 in the United States and Canada. This expansion increases the range of complex aortic anatomies that can be treated with its branched endovascular technology.

Gore reports 98.6% side-branch patency at one year for its Zone 0 and 1 clinical evidence and 99.2% left subclavian artery branch patency at one year for Zone 2. These clinical results highlight the technology's role in maintaining branch-vessel blood flow during complex aortic repair. Broader device indications create opportunities for specialized hospitals to adopt branched TEVAR procedures, strengthening Gore's position in advanced thoracic aortic treatment.

Other Important Manufacturers and Their Market Roles:

• Terumo Aortic — Develops Thoraflex Hybrid, an FDA-approved frozen elephant trunk system combining surgical and stented graft components for complex aortic arch reconstruction.

• Artivion — Supplies the E-vita Open Neo hybrid stent-graft system for aortic arch and descending thoracic repair; its European NEOS study reported 9.9% one-year mortality among 161 participants.

• Getinge — Provides Hemashield Platinum woven aortic grafts for open cardiovascular reconstruction, supporting demand for conventional surgical aortic repair.

• Cook Medical — Supplies Zenith Alpha thoracic endovascular graft technologies, including Zenith Alpha 2, which incorporates an approved CO2 flushing protocol for TEVAR procedures.

 

Analyst Commentary: How Will Branched TEVAR and Elective Repair Shape the Next Phase of Market Growth?

The Thoracic Aortic Aneurysm Market is witnessing a shift toward minimally invasive and anatomy-specific treatment approaches, particularly for complex aortic arch and descending thoracic aneurysms. Branched endovascular repair and frozen elephant trunk procedures are expanding treatment possibilities for patients with complex aortic disease. Earlier diagnosis, improved imaging, and increasing access to specialized aortic centers are expected to support elective repair volumes, while the growing complexity of interventions will drive demand for advanced stent-graft and hybrid repair technologies.

 

Thoracic Aortic Aneurysm Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 770 Million
Revenue Forecast in 2032	USD 1.33 Billion
Overall Growth Rate	CAGR of 8.1% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million/Billion, CAGR (2026 – 2032)
Segmentation	By Treatment Approach, By Product Type, By Aneurysm Location, By Procedure Urgency, By End User, By Geography
By Treatment Approach	Thoracic Endovascular Aortic Repair (TEVAR), including Branched Endovascular Repair; Hybrid/Open-Stent Repair, including Frozen Elephant Trunk Procedures; Conventional Open Surgical Repair
By Product Type	Thoracic Endovascular Stent Grafts—Standard and Branched; Hybrid/Open-Stent Graft Systems; Conventional Surgical Aortic Grafts; Procedure-Specific Accessories
By Aneurysm Location	Aortic Root and Ascending Aortic Aneurysms, Aortic Arch Aneurysms, Descending Thoracic Aortic Aneurysms
By Procedure Urgency	Elective Repair, Urgent/Emergency Repair
By End User	Multispecialty Hospitals, Specialized Cardiac and Vascular Hospitals
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, Spain, China, Japan, South Korea, India, Australia, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Increasing adoption of minimally invasive thoracic endovascular aortic repair, branched stent-graft innovation, rising demand for complex aortic arch repair, advanced cardiovascular imaging and 3D procedural planning, growing use of hybrid and frozen elephant trunk procedures, earlier aneurysm detection, expansion of specialized cardiovascular centers, and increasing access to advanced endovascular treatment technologies
Customization Option	Available upon request